Innovative Medicine
-
SIMPONI® Receives European Commission Approval For Treatment Of Moderately To Severely Active Ulcerative Colitis
First and Only Subcutaneous Biologic Treatment Administered Every Four Weeks Approved for Ulcerative Colitis -
STELARA® (Ustekinumab) Receives FDA Approval To Treat Active Psoriatic Arthritis
First and Only Anti-IL-12/23 Treatment Approved for Adult Patients Living with Psoriatic Arthritis -
STELARA® Receives European Commission Approval For Treatment Of Active Psoriatic Arthritis
Approval marks a new biologic treatment with alternative mechanism for complex inflammatory disease -
-
Pooled Analysis Confirms XARELTO® has Similar Efficacy and Reduces the Incidence of Major Bleeding by Nearly Half Compared to Standard of Care in Treatment of DVT and PE
Analysis Published in the Thrombosis Journal -
-
Johnson & Johnson Completes Acquisition Of Aragon Pharmaceuticals, Inc.
Late-Stage Prostate Cancer Treatment Strengthens Oncology Pipeline -
European Commission Approves VELCADE® As A Frontline Induction Therapy Before Stem Cell Transplantation
Decision could significantly improve transplant outcomes for patients with multiple myeloma -
STELARA® Receives CHMP Positive Opinion For Treatment Of Psoriatic Arthritis
STELARA Recommended for Approval in Adult Patients with Active Psoriatic Arthritis